KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Total Current Liabilities (2018 - 2025)

Aurinia Pharmaceuticals' Total Current Liabilities history spans 7 years, with the latest figure at $93.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 4.13% year-over-year to $93.7 million; the TTM value through Dec 2025 reached $93.7 million, down 4.13%, while the annual FY2025 figure was $93.7 million, 4.13% down from the prior year.
  • Total Current Liabilities reached $93.7 million in Q4 2025 per AUPH's latest filing, up from $76.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $97.8 million in Q4 2024 to a low of $21.2 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $59.0 million, with a median of $65.0 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: soared 78.08% in 2023, then decreased 4.13% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $40.6 million in 2021, then increased by 13.44% to $46.1 million in 2022, then skyrocketed by 67.41% to $77.2 million in 2023, then rose by 26.66% to $97.8 million in 2024, then decreased by 4.13% to $93.7 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Total Current Liabilities are $93.7 million (Q4 2025), $76.2 million (Q3 2025), and $78.3 million (Q2 2025).